Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer

Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684 Gillett C, Fantl V, Smith R et al (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812–1817 Michalides R, Hageman P, van Tinteren H et al (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728–734 van Diest PJ, Michalides RJ, Jannink L et al (1997) Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 150:705–711 Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98:415–418 Hwang TS, Han HS, Hong YC et al (2003) Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53:74–80 Han S, Park K, Bae BN et al (2003) Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 10:141–144 Elsheikh S, Green AR, Aleskandarany MA et al (2007) CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat Doisneau-Sixou SF, Sergio CM, Carroll JS et al (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10:179–186 Gillett C, Smith P, Gregory W et al (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92–99 Reis-Filho JS, Savage K, Lambros MB et al (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19:999–1009 Stendahl M, Kronblad A, Ryden L et al (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90:1942–1948 Ahnstrom M, Nordenskjold B, Rutqvist LE et al (2005) Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91:145–151 Jirstrom K, Stendahl M, Ryden L et al (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65:8009–8016 Neuman E, Ladha MH, Lin N et al (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338–5347 Keyomarsi K, Conte D Jr, Toyofuku W et al (1995) Deregulation of cyclin E in breast cancer. Oncogene 11:941–950 Nielsen NH, Arnerlov C, Emdin SO et al (1996) Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874–880 Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300 Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575 Han S, Park K, Bae BN et al (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83:241–247 Rudolph P, Kuhling H, Alm P et al (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105:674–680 Kuhling H, Alm P, Olsson H et al (2003) Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199:424–431 Lindahl T, Landberg G, Ahlgren J et al (2004) Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 25:375–380 Chappuis PO, Donato E, Goffin JR et al (2005) Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16:735–742 Spruck C, Sun D, Fiegl H et al (2006) Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355–7360 Sieuwerts AM, Look MP, Meijer-van Gelder ME et al (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319–3328 Span PN, Tjan-Heijnen VC, Manders P et al (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898–4904 Akli S, Zheng PJ, Multani AS et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208 Desmedt C, Ouriaghli FE, Durbecq V et al (2006) Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer 119:2539–2545 Porter PL, Barlow WE, Yeh IT et al (2006) p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98:1723–1731 Loden M, Stighall M, Nielsen NH et al (2002) The cyclin D1 high and cyclin E high subgroups of breast cancer: Separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21:4680–4690 Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531 Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575–580 Eerola H, Blomqvist C, Pukkala E et al (2000) Familial breast cancer in southern finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148 Eerola H, Heikkila P, Tamminen A et al (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7:R93–R100 Tanner M, Gancberg D, Di Leo A et al (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467–1472 Lassus H, Leminen A, Vayrynen A et al (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92:31–39 Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103 Aaltonen K, Ahlin C, Amini RM et al (2006) Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 94:1697–1702 Ahlin C, Aaltonen K, Amini RM et al (2007) Ki-67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491–498 Lamb J, Ladha MH, McMahon C et al (2000) Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20:8667–8675 Grillo M, Bott MJ, Khandke N et al (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95:185–194 Berglund P, Stighall M, Jirstrom K et al (2007) Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J Clin Pathol Berglund P, Stighall M, Jirstrom K et al (2005) Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. Cancer Res 65:9727–9734 Potemski P, Kusinska R, Watala C et al (2006) Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25:59–64